In today’s recent session, 0.8 million shares of the Stoke Therapeutics Inc (NASDAQ:STOK) have been traded, and its beta is 0.79. Most recently the company’s share price was $11.28, and it changed around -$0.77 or -6.39% from the last close, which brings the market valuation of the company to $584.98M. STOK at last check was trading at a discount to its 52-week high of $16.40, offering almost -45.39% off that amount. The share price’s 52-week low was $3.35, which indicates that the recent value has risen by an impressive 70.3% since then. We note from Stoke Therapeutics Inc’s average daily trading volume that its 3-month average coming to 1.14 million.

Stoke Therapeutics Inc (NASDAQ:STOK) trade information

Instantly STOK has been showing red trend so far today with a performance of -6.39% on intraday trading today. The performance over the last five days has remained in the red territory. The company’s shares are currently up 114.45% year-to-date, but still down -7.62% over the last five days. On the other hand, Stoke Therapeutics Inc (NASDAQ:STOK) is 88.31% up in the 30-day period.

The consensus price target as assigned by Wall Street analysts is $33.67, which translates to bulls needing to increase their stock price by 66.5% from its current value. Analyst projections state that STOK is forecast to be at a low of $21 and a high of $58.

Stoke Therapeutics Inc (STOK) estimates and forecasts

Stoke Therapeutics Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 204.86 percent over the past six months and at a 4.20% annual growth rate that is well below the industry average of 13.30%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will loss -15.10% in revenue this quarter, and will report an increase of 21.70% in the next quarter. The year-over-year growth rate is expected to be 40.40%, up from the previous year.

Consensus estimates provided by 7 financial analysts predict the company will bring in an average of $3.21 million in revenue for the current quarter. 7 analysts expect Stoke Therapeutics Inc to make $3.36 million in revenue for the quarter ending Jun 2024. The company’s sales for the same quarters a year ago were $5.15 million and -$2.48 million respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -37.70%. Forecasts for the next quarter put sales growth at -235.40%.

Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -44.06%.